Compare Quest Diagnostics Inc (DGX) vs FTAI Aviation Ltd (FTAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs FTAI Aviation Ltd — how do they compare? Quest Diagnostics Inc trades at $230.97 (market cap $25.48B), while FTAI Aviation Ltd trades at $169.97 (market cap $17.57B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and FTAI Aviation Ltd for 23 Days on average.
| DGX | FTAI | |
|---|---|---|
Market Cap | $25.48B | $17.57B |
Volume | 941,866 | 1,905,014 |
Sector | Health | Industrials |
52-Week High | $247.45 | $310.04 |
52-Week Low | $173.49 | $152.80 |
Typical Hold Time | 56 Days | 23 Days |
Enterprise Value | $31.23B | $20.69B |
Dividend Yield | 1.49% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.81, up 1.68% today, with a bullish earnings trend after beating EPS estimates for three consecutive quarters. The stock shows a mixed technical picture with a bearish overall signal but trades near key support at $228. Revenue growth accelerated to $11.04B in 2025, and the company maintains solid profitability with a 9.19% net income margin. Recent news highlights growth in consumer testing and a partnership with Apple Health, though Medicare reimbursement cuts pose a headwind.
The outlook is cautiously optimistic, supported by strong fundamentals and a consensus price target of $250 offering 8% upside. Key opportunities include demand for advanced diagnostics and AI adoption, while risks center on regulatory pressure and rising debt levels. Analyst sentiment is mixed with a slight hold bias, reflecting balanced growth prospects against near-term challenges.
FTAI Aviation trades at $169.97, down 2.78% with a bearish technical signal despite unanimous analyst buy ratings. The company reported strong 2025 results with $2.51B revenue and $501M net income, though recent quarters missed EPS expectations. Recent developments include a $500M share repurchase program, acquisition of 27 Boeing aircraft, and expanded Asia-Pacific maintenance partnerships, signaling strategic growth initiatives.
FTAI presents a compelling growth story with 100% analyst buy consensus and $321.25 price target representing 89% upside. However, investors face risks from consecutive earnings misses, negative operating cash flow, and declining profit margins. The technical bearish trend and high valuation multiples (P/E 37.35, P/B 43.49) require careful monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About FTAI Aviation Ltd
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →
